Novo Nordisk, Pfizer and Metsera
Digest more
Novo Nordisk to sell weight loss drug Poviztra
Digest more
Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market served by Alnylam,
Danish drugmaker Novo Nordisk on Tuesday cut the price of its blockbuster weight-loss drug, Wegovy, by up to 33% in India, according to a document seen by Reuters.
After [losing out to Pfizer](
Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more about NVO stock here.
A drug executive collapsed in the Oval Office while President Donald Trump was announcing a deal with drugmakers to reduce prices. Here's what we know.
Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to know and Medicare coverage
Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new pricing initiative.
Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities. Learn why NVO stock is a buy.
Feedback